Skip to main content
Clinical Trials/NCT06918327
NCT06918327CompletedNot Applicable

The Power of Concentrated Growth Factor: A New Era in Pain Management in Third Molar Surgery

Ege University1 site in 1 country49 target enrollmentStarted: May 1, 2017Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
49
Locations
1
Primary Endpoint
Postoperative pain on CGF-applied and CGF free sides in bilateral impacted third molar surgery

Study Overview

Brief Summary

The purpose of this study is to evaluate the effects of concentrated growth factor (CGF) on pain after bilateral impacted third molar surgery and to determine its contribution to the healing process.

The main question it aims to answer is:

Is CGF effective on reducing the pain in impacted third molar surgery? Researchers compare the pain on the CGF-applied and CGF free sides after impacted third molar surgery. Postoperative pain is assessed using the Visual Analogue Scale. TThe postoperative outcomes including pain are clinically assessed at different-time intervals (1-7 days).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Eligibility Criteria

Ages
18 Years to 40 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Patients with bilateral, symmetrical, bone-retained (vertical, mesioangular, horizontal) impacted wisdom teeth in the mandible, regardless of gender
  • •Patients without any systemic disease
  • •Patients who have been informed about the duration, purpose and requirements of the study and who have signed the informed consent form voluntarily.

Exclusion Criteria

  • •Having a disease affecting general health that requires the application of prophylactic antimicrobial agents
  • •Having a systemic viral, fungal or bacterial infection
  • •Patients with acute or chronic maxillary sinusitis
  • •Suspected or diagnosed pregnancy and nursing mothers
  • •Patients with heart and vascular diseases
  • •Patients with liver disease, haematological disease and neoplastic disease
  • •Patients who have recently received anti-inflammatory therapy
  • •Patients with chronic medication use (antihistamines, NSAIDs, steroids and antidepressants)
  • •Patients predisposed to psychotic or psychopathic tendencies
  • •Patients with rheumatic diseases, blood diseases, diabetes mellitus
  • •Patients at cardiological risk of infective endocarditis
  • •Patients under antibiotic pressure

Arms & Interventions

CGF

Experimental

Participants received CGF after the operation on one side

Intervention: Concentrated Growth Factor (Other)

CGF

Experimental

Participants received CGF after the operation on one side

Intervention: non-CGF (Other)

non-CGF

No Intervention

The other extraction socket is left empty

Outcomes

Primary Outcomes

Postoperative pain on CGF-applied and CGF free sides in bilateral impacted third molar surgery

Time Frame: The postoperative outcomes including pain are clinically assessed at different-time intervals (1st, 2nd, 3rd, 4th, 5th, 6th and 7th days).

The primary outcome measure is postoperative pain on CGF-applied and CGF free sides in bilateral impacted third molar surgery. Postoperative pain is assessed using the Visual Analogue Scale (VAS). Patients are asked to mark the pain they felt on the scale (10 cm long line) on the (1-7) days after the operation. The end of the line indicates unbearable pain, the beginning indicates no pain.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Mert Zeytinoğlu

Assoc. Prof. Dr.

Ege University

Study Sites (1)

Loading locations...

Similar Trials